Latest & greatest articles for infliximab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infliximab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infliximab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infliximab

81. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199) Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | Guidance and guidelines | NICE Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis Technology appraisal guidance [TA199] Published date: 25 August 2010 Share Guidance on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults (...) . The recommendations also apply to biosimilar products of these technologies that have a marketing authorisation allowing the use of the biosimilar for the same indication. This guidance replaces NICE technology appraisal guidance on: etanercept and infliximab for the treatment of psoriatic arthritis (TA104) and adalimumab for the treatment of psoriatic arthritis (TA125). Guidance development process Next review date: This guidance will be reviewed if there is new evidence. Your responsibility The recommendations

National Institute for Health and Clinical Excellence - Technology Appraisals2010

82. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy

Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy 19351624 2009 07 16 2009 09 03 2015 11 19 1468-2060 68 8 2009 Aug Annals of the rheumatic diseases Ann. Rheum. Dis. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. 1285-9 10.1136/ard.2008.090860 To evaluate the effect of infliximab dose escalation in incomplete responders in a randomised (...) controlled trial. 141 rheumatoid arthritis (RA) patients treated with infliximab for 12 months (3 mg/kg; intervals 0, 2, 6 and then 8 weeks) who responded to the drug (disease activity score in 28 joints (DAS28) decrease >1.2) but who were not in remission (DAS28 >2.6) were enrolled into the study. Patients were randomly assigned into arm A, 3 mg/kg, and arm B, 5 mg/kg infliximab every 8 weeks. Outcome measures included the DAS28, its components and C-reactive protein (CRP). There were no significant

EvidenceUpdates2009

83. Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: A clinical randomized trial

Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: A clinical randomized trial 19565559 2009 07 14 2009 09 17 2015 11 19 0004-3591 61 7 2009 Jul 15 Arthritis and rheumatism Arthritis Rheum. Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial. 974-8 10.1002/art.24513 To evaluate the efficacy and safety of intraarticular infliximab compared with intraarticular methylprednisolone in patients (...) with gonarthritis. In 23 patients with recurrent gonarthritis despite previous intraarticular corticosteroid therapy, a total of 41 intraarticular injections (20 infliximab and 21 methylprednisolone) were performed in 28 knees. Initial therapy was randomly assigned, and crossover therapy was eligible within 3 months. The clinical effect was assessed during 6 months of followup. The primary outcome was event-free survival, defined as the time after treatment until local retreatment was performed

EvidenceUpdates2009

86. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab

Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab Ma C, Panaccione R, Heitman SJ, Devlin SM, Ghosh S, Kaplan GG CRD summary The review concluded that adalimumab was an efficacious therapy for Crohn’s disease patients (...) who discontinued infliximab. Given the lack of quality assessment and other methodological weaknesses, the reliability of the authors’ conclusions is uncertain. Authors' objectives To assess the efficacy of adalimumab in Crohn’s disease patients who are infliximab primary or secondary nonresponders. Searching EMBASE and MEDLINE were searched between 1966 and May 2009 for articles in any language. Search terms were reported. Conference abstracts from American Gastroenterological Association (2006

DARE.2009

87. A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis

A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis A meta-analysis of the efficacy and safety of using infliximab for the treatment of rheumatoid arthritis Wiens A, Correr CJ, Venson R, Grochocki MC, Otuki MF, Pontarolo R CRD summary The authors concluded that infliximab was more effective than placebo in adults with rheumatoid arthritis (...) . Effects were more apparent in the short-term and seemed to decrease with longer durations. There were some methodological problems with the review, but the authors’ conclusions are based on the evidence and appear to be appropriate. Authors' objectives To evaluate the efficacy and safety of infliximab for the treatment of rheumatoid arthritis. Searching MEDLINE, EMBASE, the Cochrane Library, SCIELO, LILACS and the International Pharmaceutical Abstracts were searched for articles in any language

DARE.2009

88. Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost and health effects of strategies for the treatment of hypothetical 40-year-old patients with moderate-to-severe active refractory ulcerative colitis. The authors concluded that infliximab was not cost-effective, in the short-term (five years), at the accepted willingness-to-pay threshold. The methods were good and they and the results

NHS Economic Evaluation Database.2009

89. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.

Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. 19665644 2009 08 11 2009 09 08 2015 11 19 1474-547X 374 9688 2009 Aug 08 Lancet (London, England) Lancet Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised (...) trial. 459-66 10.1016/S0140-6736(09)60944-2 New treatment strategies for early rheumatoid arthritis are evolving rapidly. We aimed to compare addition of conventional disease-modifying antirheumatic drugs (sulfasalazine and hydroxychloroquine) with addition of a tumour necrosis factor antagonist (infliximab) to methotrexate in patients with early rheumatoid arthritis. We undertook a randomised trial in 15 rheumatology units in Sweden. We enrolled patients with early rheumatoid arthritis (symptom

Lancet2009

90. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis

A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis 18729845 2008 10 30 2009 02 20 2015 11 19 1365-2036 28 10 2008 Nov 15 Alimentary pharmacology & therapeutics Aliment. Pharmacol. Ther. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. 1230-9 10.1111/j.1365-2036.2008.03839.x Infliximab (IFX) has been shown to be efficacious (...) Department of Gastroenterology, Castle Hill Hospital, Cottingham and Hull York Medical School, UK. Punekar Y S YS Morris J J Fortun P P eng Journal Article Research Support, Non-U.S. Gov't 2008 08 24 England Aliment Pharmacol Ther 8707234 0269-2813 0 Anti-Inflammatory Agents 0 Antibodies, Monoclonal B72HH48FLU Infliximab IM Anti-Inflammatory Agents administration & dosage economics Antibodies, Monoclonal administration & dosage economics Colitis, Ulcerative drug therapy economics Cost-Benefit Analysis

EvidenceUpdates2008

91. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period

Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period 18759257 2008 09 08 2008 10 21 2015 11 19 0004-3591 59 9 2008 Sep 15 Arthritis and rheumatism Arthritis Rheum. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. 1270-8 10.1002/art.24001 To assess safety and efficacy of infliximab in patients with ankylosing spondylitis (AS) through 102 weeks. Patients (n = 279) with active AS were randomized to either (...) group 1 (n = 78; placebo through week 24 and then infliximab 5 mg/kg from weeks 24 through 96) or group 2 (n = 201; infliximab 5 mg/kg through week 96). The primary efficacy end point at week 24 (>or=20% improvement in the ASsessment in Ankylosing Spondylitis International Working Group criteria [ASAS20]) was assessed with an intent-to-treat analysis of observed data. More patients in group 2 than group 1 achieved the ASAS20 response at week 24 (61.2% versus 19.2%; P < 0.001). By week 102, groups 1

EvidenceUpdates2008

92. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate 18055472 2008 07 14 2008 08 11 2016 12 15 1468-2060 67 8 2008 Aug Annals of the rheumatic diseases Ann. Rheum. Dis. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study (...) in patients with rheumatoid arthritis and an inadequate response to methotrexate. 1096-103 This double-blind trial evaluated the efficacy and safety of abatacept or infliximab vs placebo. The primary objective of this study was to evaluate the mean change from baseline in Disease Activity Score (based on erythrocyte sedimentation rates; DAS28 (ESR)) for the abatacept vs placebo groups at day 197. Patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) were randomised 3:3:2

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

93. Withdrawal of immunosuppression in Crohn`s disease treated with scheduled infliximab maintenance: a randomized trial

Withdrawal of immunosuppression in Crohn`s disease treated with scheduled infliximab maintenance: a randomized trial 18440315 2008 06 13 2008 07 07 2015 11 19 1528-0012 134 7 2008 Jun Gastroenterology Gastroenterology Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. 1861-8 10.1053/j.gastro.2008.03.004 The benefit to risk ratio of concomitant immunosuppressives with scheduled infliximab (IFX) maintenance therapy for Crohn's (...) Antibodies, Monoclonal 0 Gastrointestinal Agents 0 Immunosuppressive Agents 9007-41-4 C-Reactive Protein B72HH48FLU Infliximab E7WED276I5 6-Mercaptopurine MRK240IY2L Azathioprine YL5FZ2Y5U1 Methotrexate AIM IM Gastroenterology. 2008 Jun;134(7):2161-3 18482585 Gastroenterology. 2008 Dec;135(6):2156-7 19013168 Curr Gastroenterol Rep. 2008 Dec;10(6):565-6 19006611 6-Mercaptopurine administration & dosage Adult Anti-Inflammatory Agents administration & dosage adverse effects pharmacokinetics Antibodies

EvidenceUpdates2008

94. Review and clinical perspectives for the use of infliximab in ulcerative colitis

Review and clinical perspectives for the use of infliximab in ulcerative colitis 18354755 2008 03 20 2008 05 29 2017 02 20 0835-7900 22 3 2008 Mar Canadian journal of gastroenterology = Journal canadien de gastroenterologie Can. J. Gastroenterol. Review and clinical perspectives for the use of infliximab in ulcerative colitis. 261-72 Infliximab is a chimeric, monoclonal anti-tumour necrosis factor-alpha antibody. It has been previously demonstrated to be an effective treatment for patients (...) with Crohn's disease who do not achieve the desired response with conventional treatments. Although the etiology of ulcerative colitis (UC) differs from that of Crohn's disease, randomized controlled trials have demonstrated that infliximab is also beneficial for the treatment of moderate to severe UC in patients who are either intolerant of or refractory to immunosuppressant agents or steroids, or those who are steroid-dependent. A review of the literature is followed by practical recommendations

EvidenceUpdates2008 Full Text: Link to full Text with Trip Pro

96. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease (...) - modelling outcomes in active luminal and fistulizing disease in adults Lindsay J, Punekar Y S, Morris J, Chung-Faye G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The authors assessed the cost-effectiveness of infliximab for the treatment

NHS Economic Evaluation Database.2008

97. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis

A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis Tsai H H, Punekar Y S, Morris J, Fortun P Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of a scheduled maintenance treatment (SMT) with infliximab (IFX) in a hypothetical cohort of patients with moderate to severe chronic ulcerative colitis (UC).The authors concluded

NHS Economic Evaluation Database.2008

98. The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain: comparison of clinical trial and clinical practice data

The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain: comparison of clinical trial and clinical practice data The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain: comparison of clinical trial and clinical practice data The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain: comparison of clinical trial and clinical practice data Kobelt G, Sobocki P, Mulero J, Gratacos J, Collantes-Estevez (...) E, Braun J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study assessed the cost-effectiveness of infliximab for the treatment of ankylosing spondylitis (AS). The authors concluded that infliximab was a cost-effective treatment

NHS Economic Evaluation Database.2008

99. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens Zintzaras E, Dahabreh I J, Giannouli S, Voulgarelis M, Moutsopoulos H M CRD summary This review concluded (...) that infliximab at 10 mg/kg in combination with methotrexate was more effective for the treatment of active rheumatoid arthritis than methotrexate alone or in combined therapy with infliximab at 3 mg/kg, without increased adverse events. This conclusion closely reflected the results of the review but its reliability may be limited by the relative narrowness of the search. Authors' objectives To assess the efficacy and tolerability of infliximab plus methotrexate compared with methotrexate alone

DARE.2008

100. Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials

Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled (...) trials Brimhall AK, King LN, Licciardone JC, Jacobe H, Menter A CRD summary This review assessed the efficacy and safety of alefacept, efalizumab, etanercept and infliximab for treatment of moderate to severe plaque psoriasis and concluded that all treatments yielded significant improvements over placebo in the short term with an increased risk of adverse events. The authors’ conclusions from this generally well-conducted review reflected the evidence and are likely to be reliable. Authors

DARE.2008